Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox approved in EUSEM guidelines

Oct 25, 2019Mark EdwardsNews

24 October 2019

ASX Announcement

Penthrox® entered in the European Society of Emergency Medicine (EUSEM) guidelines as now being recommended and approved as first-line of treatment trauma medication.

Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been included in the new EUSEM guidelines for the Management of acute pain in emergency situations. These new guidelines are published on the EUSEM website and can be found at: https://eusem.org/education/guidelines. The Guidelines cover all aspects of acute pain management in emergency situations across Europe.

For further details please click on the following link – Penthrox approved in EUSEM guidelines

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

  • MVP Board Re-organisation

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.